


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims


1 to 31. Cancelled.

32. (Currently amended) ~~The method of claim 28, wherein the compound is A~~
method of treating Parkinson's disease, which comprises administering to a patient having Parkinson's disease a therapeutically effective amount of (R)-N-(2-(3-(acetoxymino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-7-chloro-3-oxoisindolin-4-yl)cyclopropanecarboxamide of the formula:




or a pharmaceutically acceptable salt thereof.

33. (Currently amended) ~~The method of claim 28, wherein the compound is A~~
method of treating Parkinson's disease, which comprises administering to a patient having Parkinson's disease a therapeutically effective amount of (R)-N-(2-(3-(acetoxymino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide of the formula:




or a pharmaceutically acceptable salt thereof.

34. (Currently amended) ~~The method of claim 28, wherein the compound is A~~
method of treating Parkinson's disease, which comprises administering to a patient having Parkinson's disease a therapeutically effective amount of (R)-N-(2-(3-(cyclopropanecarbonyloxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide of the formula:




or a pharmaceutically acceptable salt thereof.

35. (Currently amended) ~~The method of claim 28, wherein the compound is A~~
method of treating Parkinson's disease, which comprises administering to a patient having Parkinson's disease a therapeutically effective amount of (R)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-3-(isobutyryloxyamino)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide of the formula:




or a pharmaceutically acceptable salt thereof.

36. (Currently amended) ~~The method of claim 28, wherein the compound is A~~
method of treating Parkinson's disease, which comprises administering to a patient having Parkinson's disease a therapeutically effective amount of (R)-N-(2-(3-(3,3-dimethylbutanoyloxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide of the formula:



or a pharmaceutically acceptable salt thereof.

37. (Currently amended) ~~The method of claim 28, wherein the compound is A~~
method of treating Parkinson's disease, which comprises administering to a patient having Parkinson's disease a therapeutically effective amount of (R)-cyclopropanecarboxylic acid {2-[2-(2,2-dimethyl-propionyloxycarbamoyl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isindol-4-yl}-amide of the formula:



or a pharmaceutically acceptable salt thereof.

38. (Currently amended) The method of any one of claims 28 32 to 37, wherein the compound is administered orally.

39. (Previously presented) The method of claim 38, wherein the compound is administered in the form of a tablet or capsule.

40. (Previously presented) The method of claim 38, wherein the compound is administered in the amount of from about 10 mg to about 2,500 mg per day.

41. (Previously presented) The method of claim 40, wherein the compound is administered in the amount of from about 100 mg to about 1,200 mg per day.

42. (Previously presented) The method of claim 40, wherein the compound is administered in the amount of from about 100 mg to about 800 mg per day.

43. (New) The method of any one of claims 32 to 37, further comprising administering at least one second active ingredient, wherein the second active ingredient is a dopamine agonist that is selected from the group consisting of L-DOPA/cardidopa combination, cocaine, α -methyl-tyrosine, reserpine, tetrabenazine, benzotropine, pargyline,

fenodolpam mesylate, cabergoline, pramipexole dihydrochloride, ropinorole, cardidopa, Sinemet CR, and Symmetrel.

44. (New) The method of any one of claims 32 to 37, further comprising administering at least one second active ingredient, wherein the second active ingredient is a monoamine oxidase inhibitor (MAO) that is selected from the group consisting of iproniazid, clorgyline, phenelzine, and isocarboxazid.

45. (New) The method of any one of claims 32 to 37, further comprising administering a catechol-O-methyltransferase inhibitor, wherein the catechol-O-methyltransferase inhibitor is entacapone.

46. (New) The method of any one of claims 32 to 37, further comprising administering at least one second active ingredient, wherein the second active ingredient is an acetylcholinesterase inhibitor that is selected from the group consisting of tacrine, rivastigmine, physostigmine salicylate, physostigmine sulfate, physostigmine bromide, meostigmine bromide, neostigmine methylsulfate, ambenonim chloride, edrophonium chloride, pralidoxime chloride, obidoxime chloride, trimedoxime bromide, deacetyl monoxim, edrophonium, pyridostigmine, and demecarium.

47. (New) The method of any one of claims 32 to 37, further comprising administering at least one second active ingredient, wherein the second active ingredient is an anti-inflammatory agent that is selected from the group consisting of naproxen sodium, diclofenac sodium, dichlofenac potassium, celecoxib, sulindac, oxaprozin, diflunisal, etodolac, meloxicam, ibuprofen, ketoprofen, nabumetone, refecoxib, methotrexate, leflunomide, sulfasalazine, gold salts, PH₀-D Immune Globulin, mycophenylate mofetil, cyclosporine, azathioprine, tacrolimus, basiliximab, daclizumab, salicylic acid, acetylsalicylic acid, methylsalicylate, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, flurbiprofen, piroxicam, amproxicam, droxicam, piroxicam, tenoxicam, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone, zileuton, aurothioglucose, gold sodium thiomalate, auranofin, colchicine, allopurinol, probenecid, sulfinpyrazone, benzbromarone, and betamethasone.

48. (New) The method of any one of claims 32 to 37, further comprising administering at least one second active ingredient, wherein the second active ingredient is an antiemetic agent that is selected from the group consisting of metoclopramide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxypendyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol, thiethylperazine, thioproperazine, and tropisetron.

49. (New) The method of claim 32, wherein (R)-N-(2-(3-(acetoxymino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-7-chloro-3-oxoisindolin-4-yl)cyclopropanecarboxamide is substantially free of S isomer.

50. (New) The method of claim 33, wherein (R)-N-(2-(3-(acetoxymino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide is substantially free of S isomer.

51. (New) The method of claim 34, wherein (R)-N-(2-(3-(cyclopropanecarbonyloxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide is substantially free of S isomer.

52. (New) The method of claim 35, wherein (R)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-3-(isobutyryloxyamino)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide is substantially free of S isomer.

53. (New) The method of claim 36, wherein (R)-N-(2-(3-(3,3-dimethylbutanoyloxyamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl)-3-oxoisindolin-4-yl)cyclopropanecarboxamide is substantially free of S isomer.

54. (New) The method of claim 37, wherein (R)-cyclopropanecarboxylic acid {2-[2-(2,2-dimethyl-propionyloxycarbamoyl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isindol-4-yl}-amide is substantially free of S isomer.